Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Deferoxamine preconditioning of canine stem cell derived extracellular vesicles alleviates inflammation in an EAE mouse model through STAT3 regulation.

Park SM., Oh YH., Lim GH., Yun GH., Kim KB., An JH.

Animal Study on Immune Modulation, Autoimmune Research, published in Sci Rep (2024) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Sci Rep (2024)
Country
England
Reported sample size
—
Source database
PubMed
PMID
39164295
PMCID
PMC11335858
DOI
10.1038/s41598-024-68853-2
Citations
5

Abstract (original English)

Extracellular vesicles (EVs) from mesenchymal stem cells (MSCs), specifically those preconditioned with deferoxamine (DFO) in canine adipose tissue-derived MSCs (cAT-MSCs), were explored for treating autoimmune diseases. This study assessed the effects of DFO-preconditioned EVs (EV DFO ) in an experimental autoimmune encephalomyelitis (EAE) mouse model. cAT-MSCs were treated with DFO for 48 h, after which EVs were isolated. EAE mice received intranasal EV or EV DFO treatments and were euthanized following histopathologic analysis; RNA and protein expression levels were measured. Histologically, EV and EV DFO groups showed a significant reduction in inflammatory cell infiltration and demyelination. Immunofluorescence revealed increased CD206 and Foxp3 expression, indicating elevated M2 macrophages and regulatory T (Treg) cells, particularly in the EV DFO group. Treg cells also notably increased in the spleen of EV DFO -treated mice. STAT3 and pSTAT3 proteins were upregulated in the EAE groups compared to the naïve group. However, following EV treatment, STAT3 expression decreased compared to the EAE group, whereas pSTAT3 expression was similar in both the EV and EAE groups. In conclusion, EV DFO treatment resulted in reduced STAT3 expression, suggesting its role in T cell regulation and the potential of EV DFO in modulating the STAT3 pathway for reducing inflammation more effect

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsEncephalomyelitis, Autoimmune, ExperimentalExtracellular VesiclesSTAT3 Transcription FactorMiceDogsT-Lymphocytes, RegulatoryDeferoxamineMesenchymal Stem CellsInflammation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research